Skip to main content

Table 1 Clinicopathological features of the studied tumors

From: In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458

Tumor

Tumor features & outcome

Tumor response to the GSK2126458 treatment

Morphology

Caspase-3 activity

Immunohistochemistry

Caspase-3

Cytochrome C

Annexin A2

I

- Invasive ductal carcinoma, NOS; grade 3; CS IIB; size 4.5 cm

+

+ (↑15.7 fold)

+ (10% → 20%)

¶ (2+ → 2+)

¶ (3+ → 2+)

- ER+, PR-, Her2-neu+, Ki-67 = 70%

- k c = 0.17 μM O2 min-1 mg-1

- Age 73 yr; alive at 2 yr with lung and lymph nodes metastases

II

- Invasive ductal carcinoma, NOS, NH grade 2; CS IIB; size 4.5 cm

-

+ (↑3.6 fold)

+ (1% → 3%)

+ (2+ → 3+)

¶ (2+ → 2+)

- ER+, PR+, Her2-neu-, Ki-67 = 5%

- k c = 0.15 μMO2 min-1 mg-1

- Age 58 yr; free of disease at 18 months

III

- Invasive lobular carcinoma, NOS; NH grade 3; and lobular carcinoma in situ (60% of the tumor mass; the studied component); CS IIIA; size 6.0 cm

+

-

- (1% → 1%)

¶ (3+ → 3+)

± (!) (2+ → 3+)

- ER+, PR+, Her2-neu-, Ki-67 = 30%

- k c = 0.22 μMO2 min-1 mg-1

- Age 62 yr; free of disease at 18 months

IV

- Invasive ductal carcinoma, NOS; NH grade 2; CS IIB; size 2.3 cm

+

-

+ (1% → 2%)

+ (2+ → 3+)

+ (2+ → 3+)

- ER+, PR+, Her2-neu-, Ki-67 = 20%

- k c = 0.06 μMO2 min-1 mg-1

- Age 41 yr; free of disease at 18 month

V

- Ovarian dysgerminoma; CS 1A; size 5.0 cm

+

nd

-

ǂ (3+ → ?)

ǂ (2+ → ?)

- k c = nd

- Age 22 yr; free of disease at 18 months

VI

- Ovarian serous carcinoma; CS IIIB

-

-

- (1% → 1%)

¶ (3+ → 3+)

¶ (2+ → 2+)

- k c = nd

- Age 49 yr; free of disease at 12 months

VII

- Moderately differentiated adenocarcinoma, colorectal origin; CS IV

-

-

- (5% → 0%)

- (1+ → 1+) (↑Necrosis)

¶ (2+ → 2+)

- k c = nd

- Age 60 yr; lost to follow-up

VIII

- Poorly differentiated signet ring adenocarcinoma of gastric origin, metastatic to the ovary; CS IV

-

+

+ (2% → 4%)

¶ (3+ → 3+)

+ (2+ → 3+)

- k c = nd

- Age 66 yr; advanced disease on palliative care

  1. NOS, Not otherwise specified; ER, Estrogen receptor; PR, Progesterone receptor; k c , rate of cellular respiration; CS, clinical stage; NH grade, Nottingham histological grade; nd, not done due to insufficient tumor sample; ¶, highly positive staining in treated and untreated specimens; !, inconsistent result (Additional file 2); ǂ, highly positive staining in untreated specimen (treated specimen was lost). Values in parentheses reflect treatment-associated changes in the expression intensity.